BridgeMD
New treatment option for Acute Myeloid Leukemia
Official title Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
ClinicalTrials.gov ID: NCT07563179
What this study is testing
What is Bugitinib?
Bugitinib is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for acute myeloid leukemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, single-arm, exploratory study evaluating the combination of Bugitinib, Venetoclax, and Cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML), excluding M3 subtype. The primary objective is to assess the rate of MRD (Minimal Residual Disease) negativity and the duration of MRD-negative status following treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Participants must meet all of the following criteria:
- Age 18-70 years (inclusive), regardless of sex;
- Diagnosis of non-M3 acute myeloid leukemia (AML), and meeting at least one of the following conditions:
- Failure to achieve complete remission (CR) after standard induction chemotherapy;
- First CR duration ≤12 months;
You likely can't join if
- Participants meeting any of the following criteria will be excluded:
- Known hypersensitivity to any study drug or its excipients;
- Active central nervous system (CNS) leukemia (patients with prior CNS involvement who achieved complete remission and are clinically stable may be...
- Active, uncontrolled bacterial, viral, or systemic fungal infection;
- Known hereditary bleeding or coagulation disorders, history of non-traumatic bleeding or thromboembolism, or other conditions that may increase...
- Evidence of active infection, including:
See the full eligibility criteria
- Participants must meet all of the following criteria:
- Age 18-70 years (inclusive), regardless of sex;
- Diagnosis of non-M3 acute myeloid leukemia (AML), and meeting at least one of the following conditions:
- Failure to achieve complete remission (CR) after standard induction chemotherapy;
- First CR duration ≤12 months;
- First CR duration \>12 months, followed by relapse and failure of at least one line of standard chemotherapy;
- Relapsed disease after ≥2 prior lines of therapy;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Estimated life expectancy ≥3 months;
- Adequate organ function, defined as:
- Cardiac: left ventricular ejection fraction (LVEF) ≥50% by echocardiography, with no clinically significant ECG abnormalities;
- Renal: serum creatinine ≤2.0 × upper limit of normal (ULN) and creatinine clearance ≥60 mL/min (Cockcroft-Gault);
- Hepatic: ALT and AST ≤3.0 × ULN;
- Total bilirubin ≤2.0 × ULN (≤3.0 × ULN for patients with Gilbert syndrome);
- Oxygen saturation ≥92% on room air;
- Ability to take oral medications and comply with study procedures;
- Willingness to participate and provide written informed consent.
- Participants meeting any of the following criteria will be excluded:
- Known hypersensitivity to any study drug or its excipients;
- Active central nervous system (CNS) leukemia (patients with prior CNS involvement who achieved complete remission and are clinically stable may be eligible);
- Active, uncontrolled bacterial, viral, or systemic fungal infection;
- Known hereditary bleeding or coagulation disorders, history of non-traumatic bleeding or thromboembolism, or other conditions that may increase bleeding risk;
- Evidence of active infection, including:
- Hepatitis B virus (HBV) infection with positive HBsAg or HBcAb and HBV DNA \>100 copies/mL;
- Hepatitis C virus (HCV) antibody positive with detectable HCV RNA;
- Human immunodeficiency virus (HIV) infection;
- Positive test for syphilis;
- Active bleeding or clinically significant bleeding tendency, including but not limited to:
- Active gastrointestinal bleeding, intracranial hemorrhage, or bleeding in other vital organs;
- Grade ≥3 bleeding event within 4 weeks prior to enrollment (per CTCAE);
- Known hereditary bleeding disorders (e.g., hemophilia);
- Severe platelet dysfunction not correctable;
- Significant cardiovascular disease, including but not limited to:
- New York Heart Association (NYHA) class III-IV heart failure;
- Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment;
- Clinically significant ventricular arrhythmias or unexplained syncope (excluding vasovagal or dehydration-related causes);
- Severe cardiomyopathy;
- History of or concurrent other malignancies (except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix);
- Clinically significant central nervous system disorders (e.g., epilepsy, stroke, psychiatric disorders) that may affect compliance or safety;
- Participation in another treatment clinical trial within 30 days prior to enrollment;
- Pregnant or breastfeeding women, or people planning pregnancy during the study period or within 6 months after the last dose and unwilling to use effective contraception;
- Known or suspected drug abuse or alcohol dependence;
- Requirement for concomitant use of strong CYP3A inhibitors or inducers that cannot be discontinued or dose-adjusted per protocol;
- Any other condition that, in the investigator's opinion, would make the subject unsuitable for participation.
The study team makes the final eligibility decision.
Where it's taking place
- Shenzhen, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenzhen, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.